Receptor Antagonists and Endocrine Therapies

Endocrine (hormonal) therapies treat cancers whose growth is driven by steroid hormones — chiefly hormone-receptor-positive breast cancer and prostate cancer — by interrupting hormone signalling rather than killing dividing cells directly. They work either by blocking the hormone receptor itself (receptor antagonists such as selective estrogen receptor modulators and anti-androgens) or by lowering the supply of the activating hormone (for example, aromatase inhibitors that block estrogen synthesis).

Definition

Endocrine cancer therapies are agents that interrupt steroid-hormone signalling in hormone-dependent tumours, either by antagonising the hormone receptor or by reducing circulating hormone levels, thereby depriving the tumour of a growth stimulus.

Scope

This topic covers the rationale of targeting hormone-dependent tumours, the two broad strategies of receptor antagonism and hormone deprivation, the main drug classes (selective estrogen receptor modulators, aromatase inhibitors, anti-androgens, and gonadotropin-releasing hormone analogues), and the importance of receptor-status biomarkers in predicting benefit. It is reference-educational and contains no dosing or individualised treatment advice.

Core questions

• Why are some cancers dependent on steroid hormones for growth?
• How does blocking the hormone receptor differ from lowering hormone supply?
• What distinguishes selective estrogen receptor modulators, aromatase inhibitors, and anti-androgens?
• Why does receptor status predict who benefits from endocrine therapy?

Key concepts

• Hormone-receptor-positive tumour
• Estrogen receptor and androgen receptor
• Selective estrogen receptor modulator (SERM)
• Aromatase inhibitor
• Anti-androgen
• Gonadotropin-releasing hormone (GnRH) analogue
• Hormone deprivation versus receptor antagonism
• Receptor status as a predictive biomarker

Key theories

Hormone-dependence and receptor blockade

Estrogen-receptor-positive breast cancers and androgen-driven prostate cancers depend on hormone-receptor signalling for proliferation; interrupting that signal — by antagonising the receptor or removing the hormone — slows tumour growth, and the magnitude of benefit tracks with receptor expression, as shown in large meta-analyses of adjuvant tamoxifen.

Mechanisms

Steroid hormones such as estrogen and androgen bind nuclear receptors that act as ligand-activated transcription factors, driving expression of genes that promote proliferation in responsive tissues and in tumours derived from them. Endocrine therapy interrupts this axis by two complementary strategies. Receptor antagonists occupy or modulate the receptor: selective estrogen receptor modulators such as tamoxifen competitively block the estrogen receptor in breast tissue, while anti-androgens block the androgen receptor in prostate cancer. Hormone-deprivation strategies lower the activating ligand instead: aromatase inhibitors block the enzyme that converts androgens to estrogens in postmenopausal women, and gonadotropin-releasing hormone analogues suppress gonadal hormone production. Because efficacy depends on the tumour expressing the relevant receptor, hormone-receptor status measured in the tumour is used to identify candidates for these therapies; receptor-negative tumours are not expected to respond.

Clinical relevance

Endocrine therapies are a foundational example of targeting a tumour's dependence on a signalling pathway rather than its proliferation directly, and receptor-status testing is a model of biomarker-guided treatment selection. This entry explains the pharmacological rationale to support understanding of how the class is categorised and acts; it is reference-educational and not a basis for individual diagnostic or treatment decisions.

Evidence & guidelines

Large patient-level meta-analyses by the Early Breast Cancer Trialists' Collaborative Group established that several years of adjuvant tamoxifen substantially reduce recurrence and mortality in estrogen-receptor-positive early breast cancer, with benefit confined to receptor-positive disease. Randomised trials such as TEAM compared tamoxifen with aromatase-inhibitor-based regimens, informing how the two strategies are sequenced. These analyses anchor endocrine therapy as a standard component of treatment for hormone-receptor-positive disease.

History

The concept of hormone-dependent cancer dates to Charles Huggins' demonstration in the 1940s that androgen deprivation controls prostate cancer, and to the identification of the estrogen receptor by Elwood Jensen. Tamoxifen, developed in the 1960s-1970s and championed mechanistically by V. Craig Jordan, became the prototype selective estrogen receptor modulator for breast cancer. Aromatase inhibitors and later-generation anti-androgens subsequently broadened the endocrine armamentarium, and large collaborative meta-analyses quantified the long-term benefits of receptor-targeted hormonal treatment.

Debates

How should receptor antagonism and hormone deprivation be sequenced or combined?

Selective estrogen receptor modulators and aromatase inhibitors act through different points in the estrogen axis, and trials such as TEAM examined whether upfront aromatase inhibition or a switch strategy is preferable, a question whose answer depends on patient and tumour characteristics.

Key figures

• V. Craig Jordan
• Elwood Jensen
• Charles Huggins
• Mitchell Dowsett

Seminal works

• ebctcg-2005
• ebctcg-2011
• jordan-2003

Frequently asked questions

What is the difference between a receptor antagonist and hormone deprivation in cancer therapy?

A receptor antagonist, such as tamoxifen, blocks the hormone receptor so the hormone cannot signal, whereas hormone deprivation, such as an aromatase inhibitor, lowers the amount of hormone produced; both interrupt the same growth-promoting axis from different points.

Why is receptor status tested before endocrine therapy?

Endocrine therapies only help tumours that depend on hormone-receptor signalling, so testing whether the tumour expresses the relevant receptor identifies who is likely to benefit; receptor-negative tumours are not expected to respond.